Olympus Corp.

Olympus Corp.

11.09
USD
+0.02
(+0.18%)
13.53BMarket Cap
Feb 12Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
536.7
558.14
587.27
540.54
574.43
580.85
575.05
567.8
584.24
695.61
762.35
870.85
908.34
- -
Basic EPS, GAAP
10.25
-6.38
45.69
31.23
41.68
5.96
39.34
10.04
90.15
113.13
199.75
102.91
61.27
- -
Free Cash Flow per Basic Share
29.95
18.77
-5.68
30.54
23.18
4.01
51.48
50.44
84.08
21.98
-18.33
109.37
16.32
- -
Dividend per Share
- -
- -
2.5
4.25
7
6.99
7.8
9.99
12.02
14.06
16.52
18.32
20.27
- -
Book Value per Share
240.6
259.65
266.52
288.13
324
322.8
288.16
306.48
400.43
510.22
649.08
666.02
736.9
710.18
Tangible Book Value per Share
113.92
127.79
134.31
163.01
199.18
198.09
153.6
126.01
176.85
272.62
415.66
422.76
468.95
393.37
Basic Weighted Avg Shares
1,329
1,370
1,370
1,370
1,369
1,367
1,313
1,287
1,284
1,268
1,214
1,145
1,113
1,096
Sales/Revenue/Turnover
713,286
764,671
804,578
740,557
786,497
793,862
755,231
730,544
750,123
881,923
925,752
997,332
1,010,676
- -
Operating Margin (%)
10.3
11.9
12.98
9.78
10.31
3.49
12.14
11.14
19.29
21.1
5.59
16.24
9.98
- -
Depreciation Expense
46,307
50,640
49,779
54,290
52,913
58,669
68,309
59,937
64,615
66,741
65,940
66,456
67,216
- -
Net Income, GAAP
13,627
-8,737
62,594
42,783
57,064
8,147
51,670
12,918
115,742
143,432
242,566
117,855
68,172
- -
Effective Tax Rate (%)
17.04
199.29
11.51
31.48
25.53
59.99
30.06
14.5
21.93
24.3
19.6
25.94
27.47
- -
Profit Margin (%)
1.91
-1.14
7.78
5.78
7.26
1.03
6.84
1.77
15.43
16.26
26.2
11.82
6.75
- -
Working Capital
300,206
202,735
190,941
219,297
208,371
168,521
172,937
251,682
318,354
264,465
368,645
254,192
269,434
260,963
LT Debt
346,814
253,286
263,731
217,193
159,183
121,628
199,897
323,735
333,846
290,087
229,628
134,117
159,700
246,427
Total Equity
331,284
357,254
366,582
396,228
444,259
442,387
371,958
395,480
511,362
641,234
757,186
751,733
812,040
755,407
Return on Invested Capital (%)
8.2
-12.17
13.02
7.02
8.65
1.7
9.95
9.83
13.48
14.04
3.8
11.36
6.69
- -
Return on Capital (%)
3.17
-2.39
9.94
7.33
9.06
1.88
8.9
2.61
14.57
15.91
24.58
12.07
7.37
- -
Return on Common Equity (%)
5.7
-2.55
17.37
11.26
13.63
1.84
12.73
3.38
25.59
24.94
34.72
15.62
8.72
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Sep'27
ST Debt
78,182
79,876
90,088
LT Borrowings
159,639
159,700
246,427
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,102
1,102
1,064
Market Capitalization
2,187,002
1,675,208
2,128,968

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Sep'27
Total Current Assets
652,650
706,308
652,664
Cash, Cash Equivalents & STI
196,742
216,459
189,842
Accounts Receivable, Net
196,882
236,833
206,788
Inventories
214,967
207,092
217,132
Total Current Liabilities
400,733
436,874
391,701
Payables & Accruals
- -
- -
- -
ST Debt
78,182
79,876
90,088
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.03%
16.02%
8.02%
Free Cash Flow
-54.96%
-187.18%
-85.5%
Net Income, GAAP
117.07%
159.09%
-42.16%
Sales/Revenue/Turnover
2.53%
6.86%
1.34%
Total Cash Common Dividend
22.73%
12.04%
7.51%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
234,821
239,208
251,192
272,111
997,332
2026
206,512
247,838
261,045
295,281
1,010,676
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
12.5
29.8
24.22
36.77
102.91
2026
7.96
18.08
12.86
22.54
61.27
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
17.98
- -
- -
- -
18.32
2026
19.98
- -
- -
- -
20.27
2027
- -
- -
- -
- -
- -

Company Description

CEO
Robert White
Full Time Employees
28,138
Sector
Health technology
Industry
Medical specialties
Address
2951, Ishikawa-machi Tokyo TY Japan 192-8507
IPO Date
May 16, 1949
Business
Olympus Corporation (7733.T), a leading global medical technology company founded in 1919 and headquartered in Tokyo, Japan, develops, manufactures and markets precision instruments primarily focused on endoscopy-enabled care, operating through Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and Others segments; its core products encompass gastrointestinal and surgical endoscopes, endotherapy devices including energy devices and guidewires, urology and gynecology products such as cystoscopes and single-use devices, respiratory-endotherapy bronchoscopes, ear-nose-throat solutions, surgical microscopes like ORBEYE, imaging platforms including VISERA 4K UHD and EasySuite 4K systems, biological and industrial microscopes, non-destructive testing equipment, X-ray fluorescence analyzers, and biomedical materials including orthopedic equipment, serving healthcare providers, researchers and industrial customers across Japan, North America, Europe, Asia, the Middle East and Oceania. The company maintains a dominant position in minimally invasive diagnosis and treatment technologies, with recent advancements including the U.S. launch of the OLYSENSE platform featuring CADe/AI solutions, distribution partnerships with W.L. Gore & Associates for EndoTherapy expansion and MacroLux Medical for single-use urology products, CE approval for three cloud-based AI medical devices with a planned 2025 AI-powered endoscopy ecosystem rollout, acquisition of a distribution business in Chile to strengthen Latin American presence, and a comprehensive corporate strategy unveiled in November 2025 emphasizing innovation-driven growth in AI, robotics and digital ecosystems alongside organizational simplification targeting 24 billion yen in run-rate savings and a net workforce reduction of approximately 2,000 positions by fiscal 2027, complemented by leadership transitions such as Keith Boettiger's appointment as Gastrointestinal Solutions Division Head effective April 2026.

Company News

  • Olympus Co. (OTCMKTS:OLYMY) Short Interest Update

  • Olympus Corporation (OLYMY) Q3 2026 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • Olympus (OTCMKTS:OCPNY) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

  • Olympus Corporation (OLYMY) Discusses New Strategic Vision and Expansion of Endoscopy-Enabled Care Prepared Remarks Transcript

  • Olympus Corporation (OLYMY) Q1 2026 Earnings Call Transcript

  • Trends Shaping Qatar's Infection Control Market 2025-2034: Featuring Sidra Medicine, BD, Condair, Sotera Health, Olympus, 3M

  • North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

  • North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key Companies - Boston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf

  • Apollo Announces Olympus Housing Capital

  • Olympus Corporation (OLYMY) Q4 2025 Earnings Call Transcript

  • Olympian Motors and Foxconn Partner to Launch Olympus OS: AI-Defined Vehicle Operating System

  • Monroe Capital Supports Olympus Partners' Acquisition of PAI Pharma

  • Monroe Capital Supports Olympus Partners' Acquisition of Accelevation Holding Company, LLC

  • Olympus Corporation (OLYMY) Q3 2025 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Q2 2025 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Q1 2025 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Q4 2024 Earnings Call Transcript

  • Olympus Corporation (OLYMY) Q3 2024 Earnings Call Transcript

  • Olympus Corporation (OCPNF) Q2 2024 Earnings Call Transcript